See more : Greenwing Resources Ltd (GW1.AX) Income Statement Analysis – Financial Results
Complete financial analysis of X4 Pharmaceuticals, Inc. (XFOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of X4 Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ragnar Metals Limited (RAG.AX) Income Statement Analysis – Financial Results
- Jioushun Construction Co., Ltd. (5547.TWO) Income Statement Analysis – Financial Results
- Elite Material Co., Ltd. (2383.TW) Income Statement Analysis – Financial Results
- Regal Real Estate Investment Trust (1881.HK) Income Statement Analysis – Financial Results
- My Size, Inc. (MYSZ.TA) Income Statement Analysis – Financial Results
X4 Pharmaceuticals, Inc. (XFOR)
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.00M | 0.00 | 3.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.99M | 1.89M | 0.00 | 672.00K | 103.00K | 195.00K | 300.00K | 400.00K |
| Gross Profit | -2.00M | -1.99M | -1.89M | 3.00M | -672.00K | 3.40M | -195.00K | -300.00K | -400.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 97.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 72.02M | 61.06M | 50.65M | 41.93M | 30.16M | 30.98M | 28.13M | 17.83M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.51M | 27.02M | 24.70M | 20.94M | 17.64M | 18.41M | 8.01M | 6.52M | 2.12M |
| Other Expenses | 0.00 | -6.27M | -3.57M | -2.11M | -1.10M | -85.00K | -16.00K | 104.00K | -77.00K |
| Operating Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Cost & Expenses | 107.52M | 88.08M | 75.35M | 62.87M | 47.80M | 46.21M | 32.27M | 21.96M | 12.67M |
| Interest Income | 4.58M | 219.00K | 10.00K | 273.00K | 1.20M | 809.00K | 214.00K | 0.00 | 0.00 |
| Interest Expense | 5.78M | 3.99M | 3.64M | 2.69M | 2.15M | 1.04M | 2.08M | 2.52M | 472.00K |
| Depreciation & Amortization | 419.00K | 1.99M | 1.89M | 1.23M | 672.00K | 103.00K | 195.00K | 300.00K | 389.00K |
| EBITDA | -107.52M | -87.57M | -85.11M | -58.07M | -51.70M | -45.89M | -31.60M | -20.16M | -12.35M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,195.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.52M | -87.57M | -85.11M | -59.87M | -51.70M | -45.89M | -36.13M | -24.35M | -14.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,995.80% | 0.00% | -1,311.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.43M | -6.27M | -3.57M | -2.11M | -1.10M | 2.86M | 2.26M | 6.48M | 1.61M |
| Income Before Tax | -101.09M | -93.84M | -88.68M | -61.98M | -52.81M | -43.02M | -33.88M | -22.98M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -2,066.10% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 78.00K | 28.00K | 17.00K | 148.00K | 3.80M | 3.90M | 1.87M | 2.62M | 395.00K |
| Net Income | -101.17M | -93.87M | -88.70M | -62.13M | -56.60M | -43.02M | -33.88M | -22.98M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -2,071.03% | 0.00% | -1,229.17% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| EPS Diluted | -0.57 | -1.48 | -3.44 | -3.09 | -4.91 | -93.73 | -98.58 | -24.76 | -14.24 |
| Weighted Avg Shares Out | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
| Weighted Avg Shares Out (Dil) | 177.81M | 63.53M | 25.75M | 20.08M | 11.53M | 459.00K | 343.64K | 928.01K | 928.01K |
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Dan Ferry - IR Paula Ragan - CEO Adam Mostafa - CFO Mark Baldry - CCO Conference Call Participants David Bautz -...
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in November 2024 Initiated global, pivotal Phase 3 trial of mavorixafor in...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on July 31, 2024, the company issued inducement awards...
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward...
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 31, 2024, the company issued inducement awards...
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of...
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2nd...
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial...
Source: https://incomestatements.info
Category: Stock Reports
What is the projected cash runway for X4 Pharmaceuticals?
X4 Pharmaceuticals Inc (NASDAQ:XFOR) ended the third quarter of 2024 with cash and equivalents of almost $136 million, providing a financial runway into late 2025.
What were X4 Pharmaceuticals’ net revenues in Q3 2024?
Revenue and Cost of Revenue: For the three months ended September 30, 2024 , X4 reported net product revenue of $0.6 million and cost of revenue of $0.2 million related to the sale of XOLREMDI.